Drugs / IIBR-100
IIBR-100
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04608305 | Oct 2020 → Oct 2022 | COVID-19 | Israel Institute for Biological Research (IIBR) | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04990466 | Sep → Dec 2021 | COVID-19 | NeuroRx, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IIBR-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04608305 ↗ |
| Known as | rVSV-SARS-CoV-2-S | “We investigated the safety and immunogenicity of the IIBR-100 (rVSV-SARS-CoV-2-S) vaccine, a recombinant VSV-ΔG-spike vaccine against SARS-CoV-2 virus.” PMID 41106035 ↗ Oct 20251“replication-competent recombinant VSVΔG-spike vaccine (rVSV-SARS-CoV-2-S, IIBR-100)” NCT04990466 ↗ |
| Known as | VSV-ΔG | “IIBR-100 (VSV-ΔG) vaccine” NCT04990466 ↗ |
| Modality | Vaccine | “a recombinant VSV-ΔG-spike vaccine against SARS-CoV-2 virus” PMID 41106035 ↗ Oct 2025 |
| Route | Intramuscular | “the subjects will receive an intramuscular injection of the IIBR-100” NCT04608305 ↗ |